Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type Two diabetes. It is used together with a diabetic diet and exercise. It is not indicated for use by itself in type one diabetes. It is taken by mouth. Effects generally begin within half an hour and can last for up to a day.
Common side effects include nausea, diarrhea, low blood sugar, and headache. Other side effects include sleepiness, skin rash, and shakiness. The dose may need to be adjusted in those with liver or kidney disease. Use during pregnancy or breastfeeding is not recommended. It works by stimulating the pancreas to release insulin and increases tissue sensitivity to insulin.
Glipizide was approved for medical use in the United States in the late nintey . It is available as a generic medication. In previous year, it was the top most commonly prescribed medication in the United States, with more than thirteen million prescriptions.
GLOBAL GLIPIZIDE MARKET SIZE AND FORECAST
The Global Glipizide Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
NEW PRODUCT LAUNCH
Apollo Pharma Glipizide Glipizide sensitizes the beta cells of pancreatic islets of Langerhans insulin response, meaning that more insulin is released in response to glucose than would be without glipizide ingestion.
Glipizide acts by partially blocking potassium channels among beta cells of pancreatic islets of Langerhans. By blocking potassium channels, the cell depolarizes, which results in the opening of voltage-gated calcium channels. The resulting calcium influx encourages insulin release from beta cells.
GLIPIZIDE belongs to the group of antidiabetic medicines called ‘sulfonylureas’ used to treat type-2 diabetes mellitus. GLIPIZIDE is prescribed for the condition of type 2 diabetes when diet and exercise alone cannot control their blood sugar levels. GLIPIZIDE works by increasing insulin production by stimulating insulin secretion from the beta cells of the pancreas, thereby reducing high blood glucose (sugar) levels.
GLIPIZIDE is not effective in people with type 1 diabetes or for treating serious hyperglycemia (high blood glucose levels). Consult your doctor before taking GLIPIZIDE if you are pregnant or breastfeeding.
GLIPIZIDE is not recommended for children. Avoid alcohol consumption while taking GLIPIZIDE as it might increase side effects. GLIPIZIDE may cause dizziness and drowsiness, so drive only if you are alert. Inform your doctor about all the medications you are taking and your health condition to rule out any unpleasant side effects.
THIS REPORT WILL ANSWER FOLLOWING QUESTIONS
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.